ACHE and Cognitive impairment: For the in vivo component, scopolamine-induced cognitive impairment—characterized by muscarinic receptor blockade, elevated hippocampal and cortical AChE activity, and reduced ACh availability—was selected to replicate central cholinergic deficiency, a fundamental AD pathological feature.